Table 1.
Clinical and MRI Characteristics in the Entire Cohort and in the Subgroups of Patients
| Cohort (N = 445) | PIRA (n = 74) | RAW (n = 17) | Patients without CDA (n = 354) | |
| Baseline demographic and clinical data | ||||
| Female, n (%) | 289 (64.9) | 50 (67.6) | 12 (70.6) | 227 (64.1) |
| Age, y, mean (SD) | 45.0 (11.4) | 49.8 (11.8) | 41.3 (8.8) | 44.2 (11.2) |
| Disease duration, y, median (IQR) | 10.3 (5.7–17.9) | 14.7 (7.3–19.9) | 8.3 (3.8–14.3) | 9.4 (5.5–17.3) |
| EDSS, median (IQR) | 2.5 (1.5–3.5) | 3.0 (2.0–4.5) | 1.5 (1.0–2.0) | 2.0 (1.5–3.5) |
| Disease course, n (%) | ||||
| RRMS, | 395 (88.8) | 49 (66.2) | 15 (88.2) | 331 (93.5) |
| SPMS | 36 (8.1) | 17 (23.0) | 2 (11.8) | 17 (4.8) |
| PPMS | 14 (3.1) | 8 (10.8) | 0 (0) | 6 (1.7) |
| Patients on DMTs, n (%) | 378 (84.9) | 58 (78.4) | 15 (88.2) | 305 (86.2) |
| Platform, n | 41 | 5 | 3 | 33 |
| Oral, n | 241 | 35 | 9 | 197 |
| Monoclonal antibodies, n | 96 | 18 | 3 | 75 |
| Patients with relapse activity in the year before baseline, n (%) | 14 (3.1) | 2 (2.7) | 1 (5.9) | 11 (3.1) |
| Patients with relapse activity in the 2 y before baseline, n (%) | 37 (8.3) | 5 (6.8) | 1 (5.9) | 31 (8.8) |
| MRI data | ||||
| MRI scans, n | 1,514 | 251 | 70 | 1,193 |
| No. of scans per patient, median (IQR) | 4 (3–4) | 3 (3–4) | 4 (3–5) | 4 (3–4) |
Abbreviations: CDA = confirmed disability accumulation; DMT = disease modifying therapy; EDSS = Expanded Disability Status Scale; IQR = interquartile range; PIRA = progression independent of relapse activity; PPMS = primary progressive multiple sclerosis; RAW = relapse-associated worsening; RRMS = relapsing-remitting multiple sclerosis; SPMS = secondary progressive multiple sclerosis.